Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T [0.03%]
基于免疫受体酪氨酸抑制基序的功能筛选鉴定出用于CAR-T的强力抑制模块
Ting Yang,Min Gao,Yufang Sun et al.
Ting Yang et al.
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies but remains limited by on-target, off-tumor toxicity and the lack of precise mechanisms to restrain a...
Application of a novel LC-MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics [0.03%]
一种新型LC-MS基蛋白质组学工作流程在生物治疗药物宿主细胞蛋白监测和风险管理中的应用
Xiaojuan Yu,Jianhui Cheng,Qianchuan Lv et al.
Xiaojuan Yu et al.
Background: Comprehensive monitoring of host cell proteins (HCPs) is essential for ensuring the quality, safety, and consistency of antibody therapeutics. Conventional enzyme-linked immunosorbent assay-based assays provid...
Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy [0.03%]
伊沃西玛和其它抗程序性死亡受体1/配体1(PD-(L)1)/血管内皮生长因子(VEGF)双特异性抗体：癌症治疗中的进展与前景
Cunnan Dong,Xue Wang
Cunnan Dong
In cancer therapy, the synergistic interaction between immunotherapy and anti-angiogenic therapy has been validated by both preclinical and clinical studies, and has laid the foundation for the development of anti-PD-(L)1/VEGF bispecific an...
A hyperimmune ovine antibody-based therapeutic candidate against Crimean-Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model [0.03%]
针对Gn和Gc糖蛋白的高免羊源单克隆抗体抗血清作为治疗剂防控克里米亚-刚果出血热病毒：小鼠模型中较高的抗体滴度及中和活性但缺乏保护力
Emma Kennedy,Stephen Findlay-Wilson,Sarah Webster et al.
Emma Kennedy et al.
Background: Crimean-Congo haemorrhagic fever virus (CCHFV) is a tick-borne pathogen that has a wide geographical range and has the potential to cause severe disease in those infected. There are no currently approved vacci...
Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond [0.03%]
新型HER3/c-Met双抗ADC(SDP1347)SDP0505的开发及其在EGFR-TKI耐药NSCLC、CRC等多种实体瘤中的抗肿瘤活性研究
Li-Min Wang,Changyong Yang,Simeng Chen et al.
Li-Min Wang et al.
Background: Despite the success of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance remains an unmet need. A...
Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy [0.03%]
IBD0333的临床前特征研究，一种新型CD24×4-1BB双特异性抗体，具有肿瘤依赖性激动剂活性用于癌症免疫治疗
Dong-Cheng Jiang,Dan-Dan Zhou,Xiao-Rui Xu et al.
Dong-Cheng Jiang et al.
Background: The immunosuppressive nature of tumor microenvironment (TME) limits the efficacy of current immunotherapies. Bispecific antibodies (bsAbs) offer a promising strategy to overcome this challenge by enabling loca...
Shuya Xu,Yunlong Wang,Yawen Yu et al.
Shuya Xu et al.
Unlike conventional monoclonal antibodies, complex biologics-such as bispecific antibodies and fusion proteins-often face challenges including lower expression levels, higher mispairing rates, and greater sensitivity to culture conditions, ...
Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates [0.03%]
优化亲和力的TROP2抗体支持抗体药物偶联物的抗肿瘤活性
Aiko Yamaguchi,Junping Hong,Leike Li et al.
Aiko Yamaguchi et al.
Background: Trophoblast cell surface antigen 2 (TROP2) is frequently overexpressed in epithelial tumors and is associated with poor prognosis, making it an attractive therapeutic target. Antibody-drug conjugates (ADCs) di...
Durable disease control following treatment with ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, in femoral osteosarcoma with lung metastases after chemotherapy failure: a case report [0.03%]
化疗失败后的股骨骨肉瘤肺转移患者使用新型Cx43半通道激动剂单克隆抗体ALMB-0168治疗后达到持续疾病控制：病例报告
Xianbiao Xie,Yiying Bian,Xiugao Yang et al.
Xianbiao Xie et al.
Limited progress has been made over the past three decades in improving survival for patients with osteosarcoma after standard therapy. ALMB0168 is a first-in-class therapeutic antibody agonist targeting Cx43 hemichannels and has demonstrat...
Analysis of the use of monoclonal antibodies in the treatment of Crohn's disease [0.03%]
单克隆抗体在治疗克罗恩病中的应用分析
Alexander V Blagov,Marina D Sazonova,Anastasia I Ryzhkova et al.
Alexander V Blagov et al.
Crohn's disease (CD) is a chronic inflammatory bowel disease with increasing global prevalence, significantly impacting patients' quality of life and healthcare costs. The introduction of monoclonal antibodies has revolutionized CD manageme...